当前位置:首页 > 报告详情

制定单克隆抗体规格.pdf

上传人: 鲁** 编号:615442 2025-03-03 32页 2.58MB

1、中国食品药品检定研究院National Institutes for Food and Drug ControlEstablishment of Specifications for Monoclonal AntibodiesChuanfei Yu PhDNational Institutes for Food and Drug ControlDisclaimerDisclaimer:This report represents only personal views and does not reflect the opinions of the regulatory authorities

2、 or the National Institutes for Food and Drug Control.National Institutes for Food and Drug Control1OverviewCompendial and regulatory requirements and experience with similar productsExamples of specification setting for purity and potencyReport Outline23Summary4National Institutes for Food and Drug

3、 ControlOverall Control Strategy for BiologicsICH Q6BNational Institutes for Food and Drug ControlComprehensive method validationICH Q6BOverall Control Strategy for BiologicsNational Institutes for Food and Drug ControlConsiderations for Specification Item SettingUsing the QbD approach,lot release&s

4、tability testing should berisk-based and address highly critical or less well-controlled attributesA specification is defined as a list of tests,references to analytical procedures,and appropriate acceptance criteria which are numerical limits,ranges,or other criteria for the tests described.ICH Q6B

5、National Institutes for Food and Drug ControlTypical Specification for Monoclonal AntibodiesNational Institutes for Food and Drug ControlICH-Q6BLinked to Manufacturing Process-Proposed specification should be based on data from manufacturing process with demonstrated manufacturing consistency.-A lac

6、k of manufacturing consistency is not a good justification for a broad specification.Account for drug substance and drug product stability-May need serval stability indicating assays to address the inherent product complexity.Linked to preclinical and clinical studies-The quality of commercial scale

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了中国食品药品检定研究院关于单克隆抗体规格设定的方法。文章首先概述了生物制品的整体控制策略,包括ICH Q6B指南和综合方法验证。接着,文章详细讨论了规格项目设定的考虑因素,如使用基于质量源于设计的(QbD)方法,基于风险的批量放行和稳定性测试,以及与制造过程、药物物质和药物产品稳定性、前期临床和临床研究以及分析程序的关联。 文章还详细介绍了如何设定规格限值,包括参考药典要求、产品理解、类似产品的经验、表征研究、结构-功能关系和产品稳定性。此外,还讨论了统计方法的选择,包括最小值、最大值、预测区间、参考区间和容许区间,以及如何使用这些方法来设定离子色谱规格和活性物质规格。 最后,文章强调了以患者为中心的规格设定策略,包括与制造过程、药物物质和药物产品稳定性、前期临床和临床研究以及分析程序的关联,以及与ICH Q6B指南的安全性、免疫原性和药代动力学考虑因素。
如何根据产品特性和稳定性设置质量标准? 如何利用统计方法确定产品质量规格? 如何确保药品质量符合患者需求?
客服
商务合作
小程序
服务号
折叠